Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Lowers Price Target to $5.6

Benzinga · 2d ago
Morgan Stanley analyst Vikram Purohit maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Equal-Weight and lowers the price target from $5.9 to $5.6.